BB Biotech AG : T2 boosté par la recovery sur les marchés et un newsflow positif
>T2 sous l’impulsion du rebond des marchés… - BB Biotech publie ce matin ses chiffres au titre du T2 2020. Le titre de la holding a gagné 32.9% en € et 32.1% en CHF sur le trimestre reflétant la recovery amorcée au T2 à l’instar des marchés equities. La NAV du portefeuille a progressé quant à elle de 48.2% en CHF, de 47.7% en € et de 51.2% en $ surperformant son indice de référence le NBI (Nasdaq Biotechnology Index) qui a lui gagné 26.9% (en $) sur la période. Il en ...Co.'s principal activity is to invest in biotechnology companies globally. The investments are held through its wholly-owned subsidiaries: Biotech Focus N.V., Biotech Invest N.V., Biotech Target N.V., and Biotech Growth N.V., all of which are located in Curacao. Co. acquires holdings in companies in the biotechnology growth market. The focus of the holdings is on quoted companies that are concentrating on the development and marketing of innovative medicines. For the selection of holdings, Co. relies on fundamental analysis by physicians and molecular biologists.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.